Invention Grant
- Patent Title: Targeted CD73 antibody and antibody-drug conjugate, and preparation method therefor and uses thereof
-
Application No.: US16978995Application Date: 2019-03-07
-
Publication No.: US12024565B2Publication Date: 2024-07-02
- Inventor: Ke Yu , Rui Jin , Liang Liu
- Applicant: FUDAN UNIVERSITY , Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
- Applicant Address: CN Shanghai
- Assignee: Fudan University,Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
- Current Assignee: Fudan University,Bliss Biopharmaceutical (Hangzhou) Co., Ltd.
- Current Assignee Address: CN Shangai; CN Zhejiang
- Agency: Seed IP Law Group LLP
- Priority: CN 1810188351.8 2018.03.07 CN 1810506111.8 2018.05.24
- International Application: PCT/CN2019/077369 2019.03.07
- International Announcement: WO2019/170131A 2019.09.12
- Date entered country: 2020-09-08
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K39/00 ; A61K47/68 ; A61P35/00 ; C07K16/00 ; C07K16/28 ; C07K16/40 ; C07K16/46

Abstract:
Disclosed by the present invention are a targeted CD73 antibody and an antibody-drug conjugate (ADC), and a preparation method therefor and application thereof. Further disclosed is a method for preparing the described monoclonal antibody and ADC. The monoclonal antibody and the corresponding ADC disclosed by the present invention can be efficiently and highly specifically combined with purified CD73 protein and CD73 on the surfaces of multiple tumor cells to block the catalytic activity of CD73 enzyme, and have high affinity, low immunogenicity and significant anti-tumor effect.
Public/Granted literature
- US20210024646A1 TARGETED CD73 ANTIBODY AND ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND USES THEREOF Public/Granted day:2021-01-28
Information query